IRIS Institutional Research Information System - OPENBS Open Archive UniBS

QUIROS ROLDAN, MARIA EUGENIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.105
AS - Asia 11.523
EU - Europa 8.467
SA - Sud America 2.263
AF - Africa 256
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 14
Totale 44.666
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.723
SG - Singapore 4.075
CN - Cina 3.662
BR - Brasile 1.849
UA - Ucraina 1.774
HK - Hong Kong 1.467
DE - Germania 1.425
IT - Italia 1.241
VN - Vietnam 745
FI - Finlandia 723
PL - Polonia 671
GB - Regno Unito 606
FR - Francia 569
RU - Federazione Russa 465
TR - Turchia 404
IN - India 388
IE - Irlanda 378
CA - Canada 181
BD - Bangladesh 146
AR - Argentina 139
MX - Messico 121
NL - Olanda 113
SE - Svezia 113
IQ - Iraq 90
ID - Indonesia 86
ZA - Sudafrica 83
JP - Giappone 82
EC - Ecuador 78
ES - Italia 78
AT - Austria 76
PK - Pakistan 57
CZ - Repubblica Ceca 42
SA - Arabia Saudita 41
VE - Venezuela 41
CO - Colombia 40
UZ - Uzbekistan 38
AU - Australia 36
LT - Lituania 33
BE - Belgio 32
IR - Iran 31
MA - Marocco 29
PY - Paraguay 29
CL - Cile 28
EG - Egitto 26
KE - Kenya 24
IL - Israele 22
AE - Emirati Arabi Uniti 21
JM - Giamaica 21
JO - Giordania 21
NG - Nigeria 21
UY - Uruguay 21
PE - Perù 19
DZ - Algeria 17
BO - Bolivia 16
PH - Filippine 16
TN - Tunisia 16
CH - Svizzera 15
AZ - Azerbaigian 14
EU - Europa 14
RO - Romania 14
CR - Costa Rica 12
MY - Malesia 12
KZ - Kazakistan 11
ET - Etiopia 10
HU - Ungheria 10
MU - Mauritius 10
PA - Panama 10
HN - Honduras 9
NP - Nepal 9
OM - Oman 9
AL - Albania 8
AM - Armenia 8
LV - Lettonia 8
PT - Portogallo 8
BY - Bielorussia 7
HR - Croazia 7
KR - Corea 7
TH - Thailandia 7
BG - Bulgaria 6
DO - Repubblica Dominicana 6
GE - Georgia 6
LB - Libano 6
RS - Serbia 6
SK - Slovacchia (Repubblica Slovacca) 6
TT - Trinidad e Tobago 6
BB - Barbados 5
BH - Bahrain 5
EE - Estonia 5
KG - Kirghizistan 5
MK - Macedonia 5
SI - Slovenia 5
UG - Uganda 5
LK - Sri Lanka 4
MD - Moldavia 4
MN - Mongolia 4
CI - Costa d'Avorio 3
DK - Danimarca 3
GR - Grecia 3
KH - Cambogia 3
KW - Kuwait 3
Totale 44.612
Salva come PNG Salva come JPEG
Città #
Fairfield 2.267
Singapore 2.209
Ashburn 2.097
Woodbridge 1.906
Hong Kong 1.465
Jacksonville 1.338
Houston 1.268
San Jose 1.068
Seattle 953
Cambridge 916
Wilmington 879
Ann Arbor 839
Chandler 730
The Dalles 710
Warsaw 659
Beijing 643
Princeton 634
New York 529
Nanjing 469
Helsinki 441
Los Angeles 416
Dublin 369
Lauterbourg 360
Istanbul 319
Ho Chi Minh City 249
Munich 228
Council Bluffs 212
Des Moines 196
São Paulo 191
Nanchang 190
Dallas 183
Dearborn 183
Brescia 182
Moscow 181
Buffalo 178
Milan 160
Hanoi 142
Shanghai 138
San Diego 137
Changsha 133
Chicago 131
Shenyang 131
Hebei 124
Redondo Beach 121
San Francisco 121
Jinan 113
Lancaster 99
London 98
Santa Clara 98
Tianjin 91
Frankfurt am Main 86
Nuremberg 78
Tokyo 75
Orem 74
Hangzhou 69
Turku 66
Jiaxing 65
Montreal 61
Toronto 60
Kunming 59
Rio de Janeiro 55
Chennai 54
Guangzhou 50
Brooklyn 49
Atlanta 46
Denver 45
Johannesburg 45
Zhengzhou 44
Manchester 43
Mexico City 43
Belo Horizonte 42
Phoenix 42
Verona 42
Jakarta 41
Ningbo 38
Porto Alegre 37
Brasília 36
Charlotte 36
Haiphong 36
Stockholm 36
Boston 35
Poplar 35
Rome 35
Tashkent 35
Amsterdam 34
Boardman 33
Washington 33
Curitiba 32
Düsseldorf 32
Brno 31
Da Nang 31
Baghdad 30
Brussels 30
Dong Ket 30
Kocaeli 29
Romola 29
Taizhou 29
Vienna 29
Salt Lake City 27
Lanzhou 26
Totale 29.672
Salva come PNG Salva come JPEG
Nome #
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 472
The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia 291
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study 271
Modulation of Regulatory T-cell Subsets in Very Long-term Treated Aviremic HIV(+) Patients and Untreated Viremic patients 261
Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA 250
Effectiveness of routine lumbar puncture in patients with HIV-associated Dementia (HAD) receiving suppressive antiretroviral treatment 242
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz 238
Cohort profile: Standardized management of antiretroviral therapy cohort (MASTER cohort) 225
Burden of Non-AIDS-Defining and Non-Virus-Related Cancers Among HIV-Infected Patients in the Combined Antiretroviral Therapy Era. 224
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 210
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study 206
Prevalence of integrase strand transfer inhibitors (InSTIs) resistance mutations in InSTIs-naive and -experienced HIV-1 infected patients: a single Center experience 203
Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy 202
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 201
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 201
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 197
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study 193
Hepatitis C infection influence on immune recovery in HIV-positive patients on successful HAART: The role of genotype 3 192
Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules. 187
Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study 187
Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. 183
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 183
HIV-associated asymmetric lipodystrophy syndrome 181
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 179
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 178
A first update on mapping the human genetic architecture of COVID-19 177
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 177
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 177
Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012 176
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 175
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 174
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 173
Mapping the human genetic architecture of COVID-19 171
Compassionate Use of Remdesivir for Patients with Severe Covid-19 171
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 171
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 169
Breast cancer among human immunodeficiency virus (HIV)-infected patients: the experience in Brescia, Northern Italy. 169
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 168
Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to detect osteoporosis in an HIV infected cohort 168
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 167
An enzyme-linked (alkaline phosphatase) oligonucleotide probe for the detection of serum hepatitis B virus DNA. 167
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 167
Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults 167
A population-based database to study malignancies in HIV-infected patients in the Local Health Unit of Brescia (Northern Italy), period 1999-2009 165
Lung cancer in HIV-infected patients: the experience in Brescia from 1999 to 2009 165
Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single center of Northern Italy 165
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 164
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients 163
Evidence for antigenic selection of large granular lymphocytes in a patient with Wiskott-Aldrich syndrome 162
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 162
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 162
Disseminated Histoplasmosis as AIDS-presentation. Case Report and Comprehensive Review of Current Literature 162
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 161
A COPD case-finding program in a large cohort of HIV-infected persons 161
Prevalence of non-B HIV-1 subtypes in North Italy and analysis of transmission clusters based on sequence data analysis 160
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 159
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 159
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 158
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 155
Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients 155
The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population 155
The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? 155
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 154
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 154
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 154
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 153
The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study 153
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 152
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. 152
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 151
Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir 150
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 150
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 150
Peripheral loss of regulatory T cells and polyautoimmunity in an HIV-infected patient 149
Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy,1999-2009 149
Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy 148
Analisi estensiva di sequenza dei geni della trascrittasi inversa e della proteasi di HIV-1 in una coorte clinica di pazienti HIV positivi NAIVE per la terapia antiretrovirale. 148
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 148
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study 148
The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients 147
Lymphocyte homeostasis is maintained in perinatally HIV-infected patients after three decades of life 147
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 146
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 146
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. 145
Elderly women with human immunodeficiency virus infection: is there an effect of the virus on neuropsychological prolife? 145
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort 145
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 144
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 144
CD4+ T cell evolution and predictors of its trend before and aftertenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 143
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir 142
An outbreak of Serratia marcescens bloodstream infections associated with misuse of drug vials in a surgical ward 141
Perinatally HIV-Infected Youths After Transition from Pediatric to Adult Care, a Single-Center Experience from Northern Italy 141
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 140
Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy 140
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 139
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART) 139
Immune complex p24 antigen: a new prognostic marker in human immunodeficiency virus infection 138
Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject with Solid Cancer in an Italian Multicenter Study 138
Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort 138
Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV 138
Totale 17.238
Salva come PNG Salva come JPEG
Categoria #
all - tutte 220.433
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 220.433
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021696 0 0 0 0 0 0 0 0 0 0 504 192
2021/20222.514 172 390 75 149 37 133 155 183 127 298 208 587
2022/20232.341 354 69 46 152 185 635 10 227 381 38 112 132
2023/20242.499 130 72 224 196 107 423 78 108 647 30 70 414
2024/20256.810 81 45 74 788 748 643 687 229 782 662 1.254 817
2025/202614.023 1.309 1.736 1.022 1.996 1.660 995 2.056 599 975 1.253 422 0
Totale 45.301